Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)Jianming Xu, Weiguo Su, Yanhong Deng et al.|European Journal of Cancer|2025Cited by 4